Publication | Open Access

Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02)

VaccinationVaccine DevelopmentHealthy Hiv-1-uninfected VolunteersNef ProteinsMedicineImmunologyVirologyVaccine DesignHivImmunotherapyHiv-1 Subtype BVaccine ResearchPolyvalent Vaccine